APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastric Mucosal Protective Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gastric Mucosal Protective Drug Market Analysis and Forecast 2026-2032

23 December 2025193 pages

Choose your research edition.

Industry ResearchGastric Mucosal Protective Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Mucosal Protective Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Gastric Mucosal Protective Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Mucosal Protective Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Mucosal Protective Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Gastric Mucosal Protective Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gastric Mucosal Protective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gastric Mucosal Protective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gastric Mucosal Protective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gastric Mucosal Protective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gastric Mucosal Protective Drug include Zhejaing Yuanlijian, Eisai Co., Teva, LIVZON, Guangdong Huanan Pharma, Bayer, AbbVie, Viatris and Otsuka Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gastric Mucosal Protective Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gastric Mucosal Protective Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Gastric Mucosal Protective Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastric Mucosal Protective Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gastric Mucosal Protective Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gastric Mucosal Protective Drug revenue, projected growth trends, production technology, application and end-user industry.

Gastric Mucosal Protective Drug Segment by Company

Zhejaing Yuanlijian

Eisai Co.

Teva

LIVZON

Guangdong Huanan Pharma

Bayer

AbbVie

Viatris

Otsuka Pharmaceutical

Nostrum Pharmaceuticals

Endo International

Astellas Pharma

Amneal Pharmaceuticals

Gastric Mucosal Protective Drug Segment by Type

Rebamipide

Sucralfate

Bismuth Potassium Citrate

Other

Gastric Mucosal Protective Drug Segment by Application

Hospital

Retail Pharmacy

Other

Gastric Mucosal Protective Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gastric Mucosal Protective Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gastric Mucosal Protective Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastric Mucosal Protective Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gastric Mucosal Protective Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Rebamipide Major Player Table 3. Sucralfate Major Player Table 4. Bismuth Potassium Citrate Major Player Table 5. Other Major Player Table 6. Global Gastric Mucosal Protective Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Retail Pharmacy Major Player Table 9. Other Major Player Table 10. Gastric Mucosal Protective Drug Industry Trends Table 11. Gastric Mucosal Protective Drug Industry Drivers Table 12. Gastric Mucosal Protective Drug Industry Opportunities and Challenges Table 13. Gastric Mucosal Protective Drug Industry Restraints Table 14. Global Gastric Mucosal Protective Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Gastric Mucosal Protective Drug Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Gastric Mucosal Protective Drug Market Share by Region (2021-2026) Table 17. Global Gastric Mucosal Protective Drug Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Gastric Mucosal Protective Drug Market Share by Region (2027-2032) Table 19. Global Gastric Mucosal Protective Drug Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Gastric Mucosal Protective Drug Revenue Market Share by Players (2021-2026) Table 21. Global Gastric Mucosal Protective Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Gastric Mucosal Protective Drug Key Players Headquarters & Area Served Table 23. Global Gastric Mucosal Protective Drug Players, Product Type & Application Table 24. Global Gastric Mucosal Protective Drug Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Gastric Mucosal Protective Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Gastric Mucosal Protective Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gastric Mucosal Protective Drug Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Gastric Mucosal Protective Drug Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Gastric Mucosal Protective Drug Revenue Market Share by Type (2021-2026) Table 31. Global Gastric Mucosal Protective Drug Revenue Market Share by Type (2027-2032) Table 32. Global Gastric Mucosal Protective Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Gastric Mucosal Protective Drug Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Gastric Mucosal Protective Drug Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Gastric Mucosal Protective Drug Revenue Market Share by Application (2021-2026) Table 36. Global Gastric Mucosal Protective Drug Revenue Market Share by Application (2027-2032) Table 37. Zhejaing Yuanlijian Company Information Table 38. Zhejaing Yuanlijian Business Overview Table 39. Zhejaing Yuanlijian Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Zhejaing Yuanlijian Gastric Mucosal Protective Drug Product Portfolio Table 41. Zhejaing Yuanlijian Recent Development Table 42. Eisai Co. Company Information Table 43. Eisai Co. Business Overview Table 44. Eisai Co. Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Eisai Co. Gastric Mucosal Protective Drug Product Portfolio Table 46. Eisai Co. Recent Development Table 47. Teva Company Information Table 48. Teva Business Overview Table 49. Teva Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Teva Gastric Mucosal Protective Drug Product Portfolio Table 51. Teva Recent Development Table 52. LIVZON Company Information Table 53. LIVZON Business Overview Table 54. LIVZON Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. LIVZON Gastric Mucosal Protective Drug Product Portfolio Table 56. LIVZON Recent Development Table 57. Guangdong Huanan Pharma Company Information Table 58. Guangdong Huanan Pharma Business Overview Table 59. Guangdong Huanan Pharma Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Guangdong Huanan Pharma Gastric Mucosal Protective Drug Product Portfolio Table 61. Guangdong Huanan Pharma Recent Development Table 62. Bayer Company Information Table 63. Bayer Business Overview Table 64. Bayer Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Bayer Gastric Mucosal Protective Drug Product Portfolio Table 66. Bayer Recent Development Table 67. AbbVie Company Information Table 68. AbbVie Business Overview Table 69. AbbVie Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. AbbVie Gastric Mucosal Protective Drug Product Portfolio Table 71. AbbVie Recent Development Table 72. Viatris Company Information Table 73. Viatris Business Overview Table 74. Viatris Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Viatris Gastric Mucosal Protective Drug Product Portfolio Table 76. Viatris Recent Development Table 77. Otsuka Pharmaceutical Company Information Table 78. Otsuka Pharmaceutical Business Overview Table 79. Otsuka Pharmaceutical Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Otsuka Pharmaceutical Gastric Mucosal Protective Drug Product Portfolio Table 81. Otsuka Pharmaceutical Recent Development Table 82. Nostrum Pharmaceuticals Company Information Table 83. Nostrum Pharmaceuticals Business Overview Table 84. Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio Table 86. Nostrum Pharmaceuticals Recent Development Table 87. Endo International Company Information Table 88. Endo International Business Overview Table 89. Endo International Gastric Mucosal Protective Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Endo International Gastric Mucosal Protective Drug Product Portfolio Table 91. Endo International Recent Development Table 92. Astellas Pharma Company Information Table 93. Astellas Pharma Business Overview Table 94. Astellas Pharma Gastric Mucosal Protective Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Astellas Pharma Gastric Mucosal Protective Drug Product Portfolio Table 96. Astellas Pharma Recent Development Table 97. Amneal Pharmaceuticals Company Information Table 98. Amneal Pharmaceuticals Business Overview Table 99. Amneal Pharmaceuticals Gastric Mucosal Protective Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Amneal Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio Table 101. Amneal Pharmaceuticals Recent Development Table 102. North America Gastric Mucosal Protective Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Gastric Mucosal Protective Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Gastric Mucosal Protective Drug Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Gastric Mucosal Protective Drug Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America Gastric Mucosal Protective Drug Revenue by Country (2021-2026) & (US$ Million) Table 108. North America Gastric Mucosal Protective Drug Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe Gastric Mucosal Protective Drug Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Gastric Mucosal Protective Drug Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Gastric Mucosal Protective Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Gastric Mucosal Protective Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe Gastric Mucosal Protective Drug Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe Gastric Mucosal Protective Drug Revenue by Country (US$ Million) & (2027-2032) Table 116. China Gastric Mucosal Protective Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. China Gastric Mucosal Protective Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. China Gastric Mucosal Protective Drug Revenue by Application (2021-2026) & (US$ Million) Table 119. China Gastric Mucosal Protective Drug Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Gastric Mucosal Protective Drug Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Gastric Mucosal Protective Drug Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Gastric Mucosal Protective Drug Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia Gastric Mucosal Protective Drug Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Gastric Mucosal Protective Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia Gastric Mucosal Protective Drug Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia Gastric Mucosal Protective Drug Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA Gastric Mucosal Protective Drug Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA Gastric Mucosal Protective Drug Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA Gastric Mucosal Protective Drug Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA Gastric Mucosal Protective Drug Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA Gastric Mucosal Protective Drug Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA Gastric Mucosal Protective Drug Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Gastric Mucosal Protective Drug Image Figure 2. Global Gastric Mucosal Protective Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Mucosal Protective Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Rebamipide Image Figure 5. Sucralfate Image Figure 6. Bismuth Potassium Citrate Image Figure 7. Other Image Figure 8. Global Gastric Mucosal Protective Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Gastric Mucosal Protective Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Retail Pharmacy Image Figure 12. Other Image Figure 13. Global Gastric Mucosal Protective Drug Market Size (US$ Million) & (2021-2032) Figure 14. Global Gastric Mucosal Protective Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Gastric Mucosal Protective Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Gastric Mucosal Protective Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Gastric Mucosal Protective Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Gastric Mucosal Protective Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Gastric Mucosal Protective Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Gastric Mucosal Protective Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Gastric Mucosal Protective Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Gastric Mucosal Protective Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Gastric Mucosal Protective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032) Figure 26. North America Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032) Figure 27. North America Gastric Mucosal Protective Drug Revenue Share by Country (2021-2032) Figure 28. United States Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Gastric Mucosal Protective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032) Figure 33. Europe Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032) Figure 34. Europe Gastric Mucosal Protective Drug Revenue Share by Country (2021-2032) Figure 35. Germany Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Gastric Mucosal Protective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032) Figure 45. China Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032) Figure 46. Asia Gastric Mucosal Protective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032) Figure 48. Asia Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032) Figure 49. Asia Gastric Mucosal Protective Drug Revenue Share by Region (2021-2032) Figure 50. Japan Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Gastric Mucosal Protective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032) Figure 58. SAMEA Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032) Figure 59. SAMEA Gastric Mucosal Protective Drug Revenue Share by Country (2021-2032) Figure 60. Brazil Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Gastric Mucosal Protective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Rebamipide
  • Sucralfate
  • Bismuth Potassium Citrate
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Zhejaing Yuanlijian
  • Eisai Co.
  • Teva
  • LIVZON
  • Guangdong Huanan Pharma
  • Bayer
  • AbbVie
  • Viatris
  • Otsuka Pharmaceutical
  • Nostrum Pharmaceuticals
  • Endo International
  • Astellas Pharma
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gastric Mucosal Protective Drug Market by Type
  3. 1.2.1 Global Gastric Mucosal Protective Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Rebamipide
  5. 1.2.3 Sucralfate
  6. 1.2.4 Bismuth Potassium Citrate
  7. 1.2.5 Other
  8. 1.3 Gastric Mucosal Protective Drug Market by Application
  9. 1.3.1 Global Gastric Mucosal Protective Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Gastric Mucosal Protective Drug Market Dynamics
  1. 2.1 Gastric Mucosal Protective Drug Industry Trends
  2. 2.2 Gastric Mucosal Protective Drug Industry Drivers
  3. 2.3 Gastric Mucosal Protective Drug Industry Opportunities and Challenges
  4. 2.4 Gastric Mucosal Protective Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gastric Mucosal Protective Drug Market Perspective (2021-2032)
  2. 3.2 Global Gastric Mucosal Protective Drug Growth Trends by Region
  3. 3.2.1 Global Gastric Mucosal Protective Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gastric Mucosal Protective Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Gastric Mucosal Protective Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gastric Mucosal Protective Drug Revenue by Players
  2. 4.1.1 Global Gastric Mucosal Protective Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Gastric Mucosal Protective Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gastric Mucosal Protective Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gastric Mucosal Protective Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gastric Mucosal Protective Drug Key Players Headquarters & Area Served
  7. 4.4 Global Gastric Mucosal Protective Drug Players, Product Type & Application
  8. 4.5 Global Gastric Mucosal Protective Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gastric Mucosal Protective Drug Market CR5 and HHI
  11. 4.6.3 2025 Gastric Mucosal Protective Drug Tier 1, Tier 2, and Tier 3
5 Gastric Mucosal Protective Drug Market Size by Type
  1. 5.1 Global Gastric Mucosal Protective Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gastric Mucosal Protective Drug Revenue by Type (2021-2032)
  3. 5.3 Global Gastric Mucosal Protective Drug Revenue Market Share by Type (2021-2032)
6 Gastric Mucosal Protective Drug Market Size by Application
  1. 6.1 Global Gastric Mucosal Protective Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gastric Mucosal Protective Drug Revenue by Application (2021-2032)
  3. 6.3 Global Gastric Mucosal Protective Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Zhejaing Yuanlijian
  2. 7.1.1 Zhejaing Yuanlijian Company Information
  3. 7.1.2 Zhejaing Yuanlijian Business Overview
  4. 7.1.3 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Product Portfolio
  6. 7.1.5 Zhejaing Yuanlijian Recent Developments
  7. 7.2 Eisai Co.
  8. 7.2.1 Eisai Co. Company Information
  9. 7.2.2 Eisai Co. Business Overview
  10. 7.2.3 Eisai Co. Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Co. Gastric Mucosal Protective Drug Product Portfolio
  12. 7.2.5 Eisai Co. Recent Developments
  13. 7.3 Teva
  14. 7.3.1 Teva Company Information
  15. 7.3.2 Teva Business Overview
  16. 7.3.3 Teva Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Gastric Mucosal Protective Drug Product Portfolio
  18. 7.3.5 Teva Recent Developments
  19. 7.4 LIVZON
  20. 7.4.1 LIVZON Company Information
  21. 7.4.2 LIVZON Business Overview
  22. 7.4.3 LIVZON Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 LIVZON Gastric Mucosal Protective Drug Product Portfolio
  24. 7.4.5 LIVZON Recent Developments
  25. 7.5 Guangdong Huanan Pharma
  26. 7.5.1 Guangdong Huanan Pharma Company Information
  27. 7.5.2 Guangdong Huanan Pharma Business Overview
  28. 7.5.3 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Product Portfolio
  30. 7.5.5 Guangdong Huanan Pharma Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bayer Gastric Mucosal Protective Drug Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Gastric Mucosal Protective Drug Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Gastric Mucosal Protective Drug Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 Otsuka Pharmaceutical
  50. 7.9.1 Otsuka Pharmaceutical Company Information
  51. 7.9.2 Otsuka Pharmaceutical Business Overview
  52. 7.9.3 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Product Portfolio
  54. 7.9.5 Otsuka Pharmaceutical Recent Developments
  55. 7.10 Nostrum Pharmaceuticals
  56. 7.10.1 Nostrum Pharmaceuticals Company Information
  57. 7.10.2 Nostrum Pharmaceuticals Business Overview
  58. 7.10.3 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
  60. 7.10.5 Nostrum Pharmaceuticals Recent Developments
  61. 7.11 Endo International
  62. 7.11.1 Endo International Company Information
  63. 7.11.2 Endo International Business Overview
  64. 7.11.3 Endo International Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Endo International Gastric Mucosal Protective Drug Product Portfolio
  66. 7.11.5 Endo International Recent Developments
  67. 7.12 Astellas Pharma
  68. 7.12.1 Astellas Pharma Company Information
  69. 7.12.2 Astellas Pharma Business Overview
  70. 7.12.3 Astellas Pharma Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Astellas Pharma Gastric Mucosal Protective Drug Product Portfolio
  72. 7.12.5 Astellas Pharma Recent Developments
  73. 7.13 Amneal Pharmaceuticals
  74. 7.13.1 Amneal Pharmaceuticals Company Information
  75. 7.13.2 Amneal Pharmaceuticals Business Overview
  76. 7.13.3 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
  78. 7.13.5 Amneal Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Gastric Mucosal Protective Drug Revenue (2021-2032)
  2. 8.2 North America Gastric Mucosal Protective Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Gastric Mucosal Protective Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Gastric Mucosal Protective Drug Revenue by Type (2027-2032)
  5. 8.3 North America Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Gastric Mucosal Protective Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Gastric Mucosal Protective Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Gastric Mucosal Protective Drug Revenue by Application (2027-2032)
  9. 8.5 North America Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Gastric Mucosal Protective Drug Revenue by Country
  11. 8.6.1 North America Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gastric Mucosal Protective Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Gastric Mucosal Protective Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gastric Mucosal Protective Drug Revenue (2021-2032)
  2. 9.2 Europe Gastric Mucosal Protective Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gastric Mucosal Protective Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gastric Mucosal Protective Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gastric Mucosal Protective Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gastric Mucosal Protective Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gastric Mucosal Protective Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gastric Mucosal Protective Drug Revenue by Country
  11. 9.6.1 Europe Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gastric Mucosal Protective Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gastric Mucosal Protective Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gastric Mucosal Protective Drug Revenue (2021-2032)
  2. 10.2 China Gastric Mucosal Protective Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Gastric Mucosal Protective Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Gastric Mucosal Protective Drug Revenue by Type (2027-2032)
  5. 10.3 China Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Gastric Mucosal Protective Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Gastric Mucosal Protective Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Gastric Mucosal Protective Drug Revenue by Application (2027-2032)
  9. 10.5 China Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gastric Mucosal Protective Drug Revenue (2021-2032)
  2. 11.2 Asia Gastric Mucosal Protective Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gastric Mucosal Protective Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gastric Mucosal Protective Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gastric Mucosal Protective Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gastric Mucosal Protective Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gastric Mucosal Protective Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gastric Mucosal Protective Drug Revenue by Country
  11. 11.6.1 Asia Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gastric Mucosal Protective Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gastric Mucosal Protective Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gastric Mucosal Protective Drug Revenue (2021-2032)
  2. 12.2 SAMEA Gastric Mucosal Protective Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gastric Mucosal Protective Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gastric Mucosal Protective Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gastric Mucosal Protective Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gastric Mucosal Protective Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gastric Mucosal Protective Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gastric Mucosal Protective Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gastric Mucosal Protective Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gastric Mucosal Protective Drug Revenue by Country
  11. 12.6.1 SAMEA Gastric Mucosal Protective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gastric Mucosal Protective Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gastric Mucosal Protective Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst